{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:14:41Z","timestamp":1792300481988,"version":"4.4.0"},"reference-count":54,"publisher":"FapUNIFESP (SciELO)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Bras Endocrinol Metab"],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:p>Os prolactinomas s\u00e3o os adenomas de hip\u00f3fise mais comuns e frequentemente afetam mulheres jovens, em faixa et\u00e1ria de fertilidade. A hiperprolactinemia causa hipogonadismo, irregularidade menstrual ou amenorreia em mulheres, n\u00edveis baixos de testosterona s\u00e9rica em homens e infertilidade e disfun\u00e7\u00e3o sexual em ambos os g\u00eaneros. Macroprolactinomas podem causar cefaleia, alitera\u00e7\u00e3o visual e hipopituitarismo. O tratamento cl\u00ednico com agonista dopamin\u00e9rgico \u00e9 o padr\u00e3o-ouro, sendo a cabergolina a droga de escolha por sua maior efic\u00e1cia e tolerabilidade. Em cerca de 20% dos casos, o tratamento \u00e9 parcial ou totalmente ineficaz, situa\u00e7\u00e3o na qual a cirurgia, em geral por via transesfenoidal, est\u00e1 indicada. A radioterapia \u00e9 indicada somente para controle de crescimento tumoral em casos invasivos\/agressivos. Nos macroprolactinomas invasivos, a abordagem em geral necess\u00e1ria \u00e9 a de diversas modalidades terap\u00eauticas combinadas, incluindo debulking e drogas rec\u00e9m-aprovadas como a temozolamida. Com rela\u00e7\u00e3o \u00e0 gesta\u00e7\u00e3o, a droga de escolha para induzir a ovula\u00e7\u00e3o ainda \u00e9 a bromocriptina. Nos casos de microprolactinomas e de macroprolactinomas intrasselares, o agonista dopamin\u00e9rgico pode ser suspenso ap\u00f3s a confirma\u00e7\u00e3o da gesta\u00e7\u00e3o. Nos macroprolactinomas, o manejo deve ser individualizado.<\/jats:p>","DOI":"10.1590\/0004-2730000002961","type":"journal-article","created":{"date-parts":[[2014,5,12]],"date-time":"2014-05-12T12:58:26Z","timestamp":1399899506000},"page":"118-123","source":"Crossref","is-referenced-by-count":15,"title":["Prolactinoma"],"prefix":"10.1590","volume":"58","author":[{"given":"Andrea","family":"Glezer","sequence":"first","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello D.","family":"Bronstein","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","reference":[{"issue":"3","key":"ref1","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/cncr.20412","article-title":"The prevalence of pituitary adenomas: a systematic review","volume":"101","author":"Ezzat S","year":"2004","journal-title":"Cancer"},{"issue":"5","key":"ref2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2265.1986.tb03608.x","article-title":"Asymptomatic hyperprolactinaemia and prolactinoma in the general population-mass screening by paired assays of serum prolactin","volume":"25","author":"Miyai K","year":"1986","journal-title":"Clin Endocrinol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000262536","article-title":"Prolactinomas in children and adolescents","volume":"17","author":"Colao A","year":"2010","journal-title":"Endocr Dev"},{"key":"ref4","article-title":"Multiple endocrine neoplasia type 1","volume":"1","author":"Marini F","year":"2006","journal-title":"Orphanet J Rare Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"E373","DOI":"10.1210\/jc.2009-2556","article-title":"Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study","volume":"95","author":"Daly AF","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"ref6","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1210\/jc.2011-2031","article-title":"Clinical review: pituitary carcinoma: difficult diagnosis and treatment","volume":"96","author":"Heaney APJ","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"ref7","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1210\/edrv.22.6.0451","article-title":"Dopamine as a prolactin (PRL) inhibitor","volume":"22","author":"Ben-Jonathan N","year":"2001","journal-title":"Endocr Rev"},{"issue":"4","key":"ref8","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1152\/physrev.2000.80.4.1523","article-title":"Prolactin: structure, function, and regulation of secretion","volume":"80","author":"Freeman ME","year":"2000","journal-title":"Physiol Rev"},{"key":"ref9","series-title":"Twenty-four hour secretory patterns of prolactin in women","author":"Kawagoe S","year":"1988"},{"issue":"11","key":"ref10","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/molehr\/7.11.1033","article-title":"Prolactin receptor gene expression and immunolocalization of the prolactin receptor in human luteinized granulose cells","volume":"7","author":"Vlahos NP","year":"2001","journal-title":"Mol Hum Reprod"},{"issue":"31-46","key":"ref11","article-title":"Department of Internal Medicine, University of Virginia, Charlottesville. GnRH pulses--the regulators of human reproduction","volume":"104","author":"Marshall JC","year":"1993","journal-title":"Trans Am Clin Climatol Assoc"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJM197703172961103","article-title":"Galactorrhea: a study of 235 cases, including 48 with pituitary tumors","volume":"296","author":"Kleinberg DL","year":"1977","journal-title":"N Engl J Med"},{"issue":"1-2","key":"ref13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1385\/ENDO:20:1-2:75","article-title":"Hyperprolactinemia in men: clinical and biochemical features and response to treatment","volume":"20","author":"Rosa M","year":"2003","journal-title":"Endocrine"},{"issue":"4 Pt 2","key":"ref14","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1111\/j.1743-6109.2010.01780.x","article-title":"Endocrine aspects of male sexual dysfunctions","volume":"7","author":"Buvat J","year":"2010","journal-title":"J Sex Med"},{"issue":"6","key":"ref15","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1210\/jcem-59-6-1050","article-title":"Vertebral body bonemineral content in hyperprolactinemic women","volume":"59","author":"Koppelman MC","year":"1984","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"ref16","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s12020-011-9462-5","article-title":"Vertebral fractures in males with prolactinoma","volume":"39","author":"Mazziotti G","year":"2011","journal-title":"Endocrine"},{"issue":"3","key":"ref17","first-page":"288","article-title":"High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas","volume":"39","author":"Mazziotti G","year":"2011","journal-title":"Endocrine"},{"issue":"3","key":"ref18","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11102-010-0277-9","article-title":"Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy","volume":"14","author":"Berinder K","year":"2011","journal-title":"Pituitary"},{"issue":"11","key":"ref19","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/BF03345636","article-title":"Body fat in men with prolactinoma","volume":"31","author":"Naliato EC","year":"2008","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/oby.2010.150","article-title":"BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists","volume":"19","author":"Santos Silva CM","year":"2011","journal-title":"Obesity"},{"issue":"7","key":"ref21","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2826.2010.02011.x","article-title":"Prolactin and human tumourogenesis","volume":"22","author":"Fernandez I","year":"2010","journal-title":"J Neuroendocrinol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1200\/JCO.2006.07.6356","article-title":"A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer","volume":"25","author":"Tworoger SS","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"ref23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11102-009-0214-y","article-title":"The risk for breast cancer is not evidently increased in women with hyperprolactinemia","volume":"13","author":"Dekkers OM","year":"2010","journal-title":"Pituitary"},{"issue":"2","key":"ref24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1530\/EJE-11-0076","article-title":"Cancer risk in hyperprolactinemia patients: a population-based cohort study","volume":"165","author":"Berinder K","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"ref25","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000012273","article-title":"Emotional aspects of hyperprolactinemia","volume":"67","author":"Sobrinho LG","year":"1998","journal-title":"Psychother Psychosom"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1530\/EJE-07-0259","article-title":"Quality of life is decreased in female patients treated for microprolactinoma","volume":"157","author":"Kars M","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s11102-008-0091-9","article-title":"Quality of life in women with microprolactinoma treated with dopamine agonists","volume":"11","author":"Cesar de Oliveira Naliato E","year":"2008","journal-title":"Pituitary"},{"issue":"4","key":"ref28","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1055\/s-2002-36709","article-title":"Hyperprolactinemia: etiology, diagnosis, and management","volume":"20","author":"Mah PM","year":"2002","journal-title":"Semin Reprod Med"},{"issue":"2","key":"ref29","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1442-9071.1995.tb00138.x","article-title":"Patterns of visual loss associated with pituitary macroadenomas","volume":"23","author":"Poon A","year":"1995","journal-title":"Aust N Z J Ophthalmol"},{"issue":"2","key":"ref30","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed S","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"ref31","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1365-2265.2006.02627.x","article-title":"Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma","volume":"65","author":"Karavitaki N","year":"2006","journal-title":"Clin Endocrinol"},{"issue":"7","key":"ref32","first-page":"508","article-title":"Serum prolactin concentration at presentation of non-functioning pituitary macroadenomas","volume":"36","author":"Behan LA","year":"2013","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"ref33","doi-asserted-by":"crossref","first-page":"296","DOI":"10.4158\/EP.8.4.296","article-title":"?Hookeffect? in prolactinomas: case report and review of literature","volume":"8","author":"Frieze TW","year":"2002","journal-title":"Endocr Pract"},{"issue":"3","key":"ref34","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1046\/j.1365-2265.1996.663486.x","article-title":"High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas","volume":"44","author":"St-Jean E","year":"1996","journal-title":"Clin Endocrinol"},{"key":"ref35","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/167132","article-title":"Macroprolactinemia: diagnostic, clinical, and pathogenic significance","author":"Shimatsu A","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"3","key":"ref36","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1210\/jc.2005-1831","article-title":"Human macroprolactin displays low biological activity via its homologous receptor in a new sensitive bioassay","volume":"91","author":"Glezer A","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"ref37","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s12020-012-9608-0","article-title":"Editorial: is macroprolactinemia just a diagnostic pitfall?","volume":"41","author":"Bronstein MD","year":"2012","journal-title":"Endocrine"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM199410063311403","article-title":"A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group","volume":"331","author":"Webster J","year":"1994","journal-title":"N Engl J Med"},{"issue":"3","key":"ref39","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1210\/jc.2009-2095","article-title":"Potential cardiac valve effects of dopamine agonists in hyperprolactinemia","volume":"95","author":"Valassi E","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"ref40","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1210\/jc.2007-1403","article-title":"Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline","volume":"93","author":"Colao A","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"ref41","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11102-011-0339-7","article-title":"A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas","volume":"15","author":"Boguszewski CL","year":"2012","journal-title":"Pituitary"},{"issue":"1","key":"ref42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1530\/EJE-12-0121","article-title":"Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment","volume":"167","author":"Elenkova A","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"ref43","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1210\/jc.2009-1238","article-title":"Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis","volume":"95","author":"Dekkers OM","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"ref44","article-title":"Spontaneous and medically induced cerebrospinal fluidleakage in the setting of pituitary adenomas: review of the literature","volume":"32","author":"Lam G","year":"2012","journal-title":"Neurosurg Focus"},{"issue":"5","key":"ref45","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas","volume":"27","author":"Gillam MP","year":"2006","journal-title":"Endocr Rev"},{"issue":"5","key":"ref46","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1530\/EJE-12-0236","article-title":"Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients","volume":"167","author":"Vroonen L","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"ref47","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1530\/EJE-11-1000","article-title":"Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients","volume":"166","author":"Primeau V","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"ref48","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11102-011-0348-6","article-title":"Radiotherapy for prolactin-secreting pituitary tumors","volume":"15","author":"Sheplan Olsen LJ","year":"2012","journal-title":"Pituitary"},{"issue":"12","key":"ref49","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1210\/jc.2007-2758","article-title":"Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients","volume":"93","author":"Ono M","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"ref50","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/j.1365-2265.2012.04373.x","article-title":"Temozolomide in the management of dopamine agonist-resistant prolactinomas","volume":"76","author":"Whitelaw BC","year":"2012","journal-title":"Clin Endocrinol"},{"key":"ref51","series-title":"Pituitary tumors in pregnancy","first-page":"173","volume-title":"Restoration of ovarian cyclicity and ovulation induction in hypopituitary women","author":"Serafini P","year":"2001"},{"issue":"5","key":"ref52","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrendo.2011.38","article-title":"Management of pituitary tumors in pregnancy","volume":"7","author":"Bronstein MD","year":"2011","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"ref53","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1210\/jc.2003-030979","article-title":"Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis","volume":"89","author":"Colao A","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"ref54","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1530\/EJE-09-0084","article-title":"Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment","volume":"161","author":"Ribeiro RS","year":"2009","journal-title":"Eur J Endocrinol"}],"container-title":["Arquivos Brasileiros de Endocrinologia &amp; Metabologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/abem\/v58n2\/0004-2730-abem-58-2-0118.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T16:12:07Z","timestamp":1716739927000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-27302014000200118&lng=pt&tlng=pt"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0004-27302014000200118"],"URL":"https:\/\/doi.org\/10.1590\/0004-2730000002961","relation":{},"ISSN":["0004-2730"],"issn-type":[{"value":"0004-2730","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}